However, a large number of preclinical and clinical studies demonstrated that non-selective β-AR antagonists, such as PPN or atenolol, are superior to selective β-AR antagonists at inhibiting tumor progression, cell survival and improving clinical outcome13,42–44. This evidence concerns the gene ADRB2 and neoplasm.